Literature DB >> 16530702

The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells.

H Daniel Lacorazza1, Takeshi Yamada, Yan Liu, Yasuhiko Miyata, Mariela Sivina, Juliana Nunes, Stephen D Nimer.   

Abstract

The transcriptional circuitry that regulates the quiescence of hematopoietic stem cells is largely unknown. We report that the transcription factor known as MEF (or ELF4), which is targeted by the t(X;21)(q26;q22) in acute myelogenous leukemia, regulates the proliferation of primitive hematopoietic progenitor cells at steady state, controlling their quiescence. Mef null HSCs display increased residence in G0 with reduced 5-bromodeoxyuridine incorporation in vivo and impaired cytokine-driven proliferation in vitro. Due to their increased HSC quiescence, Mef null mice are relatively resistant to the myelosuppressive effects of chemotherapy and radiation. Thus, MEF plays an important role in the decision of stem/primitive progenitor cells to divide or remain quiescent by regulating their entry to the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530702     DOI: 10.1016/j.ccr.2006.02.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  69 in total

1.  Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells.

Authors:  Takashi Asai; Yan Liu; Silvana Di Giandomenico; Narae Bae; Delphine Ndiaye-Lobry; Anthony Deblasio; Silvia Menendez; Yevgeniy Antipin; Boris Reva; Rachel Wevrick; Stephen D Nimer
Journal:  Blood       Date:  2012-07-09       Impact factor: 22.113

Review 2.  Mechanisms of self-renewal in hematopoietic stem cells.

Authors:  Zhao Wang; Hideo Ema
Journal:  Int J Hematol       Date:  2015-12-12       Impact factor: 2.490

3.  Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells.

Authors:  Vladimir Jankovic; Alessia Ciarrocchi; Piernicola Boccuni; Tony DeBlasio; Robert Benezra; Stephen D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

4.  Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties.

Authors:  Michelle B Bowie; David G Kent; Brad Dykstra; Kristen D McKnight; Lindsay McCaffrey; Pamela A Hoodless; Connie J Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

5.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2.

Authors:  Yan Liu; Cyrus V Hedvat; Shifeng Mao; Xin-Hua Zhu; Jinjuan Yao; Hoang Nguyen; Andrew Koff; Stephen D Nimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 7.  DNA damage response, redox status and hematopoiesis.

Authors:  Cary N Weiss; Keisuke Ito
Journal:  Blood Cells Mol Dis       Date:  2013-09-13       Impact factor: 3.039

8.  Self-renewal versus transformation: Fbxw7 deletion leads to stem cell activation and leukemogenesis.

Authors:  John M Perry; Linheng Li
Journal:  Genes Dev       Date:  2008-05-01       Impact factor: 11.361

9.  DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions.

Authors:  Monica Morales; Yan Liu; Evagelia C Laiakis; William F Morgan; Stephen D Nimer; John H J Petrini
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  Cyclin C regulates human hematopoietic stem/progenitor cell quiescence.

Authors:  Yasuhiko Miyata; Yan Liu; Vladimir Jankovic; Goro Sashida; Jennifer May Lee; Jae-Hung Shieh; Tomoki Naoe; Malcolm Moore; Stephen D Nimer
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.